03:50 PM EDT, 05/17/2018 (MT Newswires) -- The U.S. Food & Drug Administration (FDA) said on Thursday it is making public a list of companies that have potentially been blocking access to the samples of their branded products, raising hurdles for generic drug development and approval, sending shares of top drugmakers lower. "We hope that this increased transparency will help reduce unnecessary hurdles to generic drug development and approval," FDA Commissioner Scott Gottlieb said in a statement. Among the losers included Celgene (CELG), Johnson & Johnson (JNJ) and Novartis (NVS), which were down between 0.8% and 1.8% in late trade. "We often hear of these tactics when it comes to generic drug developer access to samples when the brand products are subject to limited distribution programs," Gottlieb said. "We'll continue to update this list periodically." (谈股论金) 469次阅读
作者: 雅歌 
, 发表于: 2018-05-21 (2156天前) @ 雅歌
- 没有文字 -
完整帖子:
- 雅歌老师，可买LABU吗？
![[ 没有文字 ]](themes/web_2.0/images/no_text.png "空帖子 / 没有文字")
- algo, 2018-05-21 ![[*]](themes/web_2.0/images/complete_thread.png "打开整个主题")
- 俺认为不要买LABU！ - 雅歌, 2018-05-21
- 老师，能说说为什么吗？我有labu,需要买labd来对冲吗？谢谢！ - 快乐退休, 2018-05-21
- LABU不要做对冲，有获利就卖掉！生药股这几年开发成功的新药很少，连大药厂都是如此，面临青黄不接，没有新药又逐渐失去专利的困境。生病的人数又不见每年都会增加！生药股基本已是涨过头了！ - 雅歌, 2018-05-21
- 乘机赶紧问问雅歌老师能谈谈celg吗？ - 熊熊, 2018-05-21
- CELG跌了很多，如果短炒的话，倒是可以在75-75.5元买进一些。大概盈利3%-5%就卖了。 - 雅歌, 2018-05-21
- CELG跌了很多，如果短炒的话，倒是可以在75-75.5元买进一些。大概盈利3%-5%就卖了。
- 03:50 PM EDT, 05/17/2018 (MT Newswires) -- The U.S. Food & Drug Administration (FDA) said on Thursday it is making public a list of companies that have potentially been blocking access to the samples of their branded products, raising hurdles for generic drug development and approval, sending shares of top drugmakers lower.
"We hope that this increased transparency will help reduce unnecessary hurdles to generic drug development and approval," FDA Commissioner Scott Gottlieb said in a statement.
Among the losers included Celgene (CELG), Johnson & Johnson (JNJ) and Novartis (NVS), which were down between 0.8% and 1.8% in late trade.
"We often hear of these tactics when it comes to generic drug developer access to samples when the brand products are subject to limited distribution programs," Gottlieb said. "We'll continue to update this list periodically." - 雅歌, 2018-05-21
- 谢雅歌老师分享 - 熊熊, 2018-05-21
- 谢雅歌老师分享
- 乘机赶紧问问雅歌老师能谈谈celg吗？
- LABU不要做对冲，有获利就卖掉！生药股这几年开发成功的新药很少，连大药厂都是如此，面临青黄不接，没有新药又逐渐失去专利的困境。生病的人数又不见每年都会增加！生药股基本已是涨过头了！
- 老师，能说说为什么吗？我有labu,需要买labd来对冲吗？谢谢！
- 俺认为不要买LABU！
打开手机微信，选【发现】->【扫一扫】左边的二维码就会在手机出现这个帖子，然后点击右上角的三个点，选分享到朋友圈。
